Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Entera Bio, Amgen ink research collaboration
March 2019
SHARING OPTIONS:

JERUSALEM—A research collaboration and license agreement is underway between Entera Bio Ltd. and Amgen, centered on inflammatory diseases and other serious illnesses. Per the terms of the agreement, Entera will apply its proprietary drug delivery platform to develop oral formulations for one preclinical large-molecule program chosen by Amgen, who has an option to select up to two additional programs. Amgen will make an initial technology access fee payment to Entera and will fund preclinical development. Entera stands to receive up to $270 million in aggregate payments based on the achievement of certain milestones, as well as royalties up to mid-single digits. Entera retains all intellectual property rights to its technology, which is licensed to Amgen solely for the chosen targets, and Amgen retains all rights to its large molecules and related improvements.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.